Nanoviricides (Nanoviricides) Total Current Assets : $3.52 Mil (As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Nanoviricides Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Nanoviricides's total current assets for the quarter that ended in Mar. 2024 was $3.52 Mil.

Nanoviricides Total Current Assets Historical Data

The historical data trend for Nanoviricides's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanoviricides Total Current Assets Chart

Nanoviricides Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Current Assets

Get a 7-Day Free Trial

2.83

13.99

20.82

14.42

8.45

Nanoviricides Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Current Assets	Get a 7-Day Free Trial															9.93	8.45	7.14	5.32	3.52

Nanoviricides Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Nanoviricides's Total Current Assets for the fiscal year that ended in Jun. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	8.15	+	0	+	0	+	0.295
	=	8.45

Nanoviricides's Total Current Assets for the quarter that ended in Mar. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	3.257	+	0	+	0	+	0.259
	=	3.52

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Nanoviricides (AMEX:NNVC) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Nanoviricides's Liquidation Value for the quarter that ended in Mar. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	3.257	-	0.813	+	0.75 * 0	+	0.5 * 0
=	2.44

Nanoviricides Total Current Assets Related Terms

Thank you for viewing the detailed overview of Nanoviricides's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanoviricides (Nanoviricides) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanoviricides Inc (AMEX:NNVC) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

NV3P:Germany

Address

1 Controls Drive, Shelton, CT, USA, 06484

Website

http://www.nanoviricides.com

Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.

Executives

Makarand Jawadakar	director	C.O NANOVIRICIDES, INC, 1 CONTROLS DRIVE, SHELTON CT 06484
Mark D. Day	director	C/O NANOVIRICIDES, INC., 1 CONTROLS DRIVE, SHELTON CT 06484
Milton Boniuk	director	C/O NANOVIRICIDES, INC., 135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516
Anil Diwan	director, 10 percent owner, officer: President	135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516
Mukund S Kulkarni	director	C/O NANOVIRICIDES, INC., 135 WOOD ST, SUITE 205, WEST HAVEN CT 06516
Meeta Vyas	officer: Chief Financial Officer	135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516
Eugene Seymour	director, 10 percent owner	666 THIRD AVENUE, NEW YORK NY 10017
Theracour Pharma, Inc.	10 percent owner	135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516